BryoLogyx Inc., announced that David Crockford has joined the Company as vice president of clinical development and logistics, a new position.
DANVILLE, CA (February 3)— BryoLogyx Inc., (www.BryoLogyx.com), a privately-held, pre-clinical company developing a new class of proprietary drugs to enhance the response rates and treatment durability of cancer immunotherapies, announced today that David Crockford has joined the Company as vice president of clinical development and logistics, a new position. Crockford joins BryoLogyx after more than 40 years at pharmaceutical and biotechnology companies, most recently at Neurotrope, where he served as Vice President of Regulatory Affairs.
David Crockford, BryoLogyx
“David brings extensive pharmaceutical development experience, a deep understanding of bryostatin, as well as and leadership in regulatory and clinical affairs,” said Thomas Loarie, President at BryoLogyx. “BryoLogyx will greatly benefit from his contributions to our team as bryostatin-1 advances towards clinical trials.”
At Neurotrope, Crockford oversaw regulatory affairs as well as manufacturing, all nonclinical toxicology and pharmacology studies and had a key role in Neurotrope’s clinical development planning, implementation and clinical studies. Most recently with Neurotrope, Crockford negotiated a CRADA with the NIH and worked with the National Cancer Institute on a potentially enabling approach to improve response to anti-CD22 targeted therapies with bryostatin 1.
Other accomplishments in Crockford’s career included implementation of regulatory and clinical strategies that enabled cost-effective, timely development of a number of innovative drugs. Before joining Neurotrope, Crockford and his team at RegeneRx Biopharmaceuticals was developing Thymosin Beta 4 (Tβ4), a naturally-occurring peptide found in almost all mammalian cells, as a treatment for chronic cutaneous and corneal eye wounds, heart disease, and multiple sclerosis. Earlier in his career, Crockford co-founded and presided over NeoBionics Corporation, one of the first publicly-held companies in the field of genetic engineering to explore the development of monoclonal antibodies for cancer diagnosis and treatment.
Crockford is author of numerous scientific publications, and is listed alternately as inventor or co-inventor on approximately twenty issued patents and patent applications.
Crockford earned a Bachelor of Arts degree in biology from Boston University’s College of Liberal Arts (now, the College of Arts and Sciences) and completed a Princeton University sponsored course study and seminar in biochemistry and clinical chemistry. Other academic milestones included Serono Symposia course studies in reproductive medicine at both the C.S. Mott Center for Human Growth and Development at Wayne State University and the UCLA Medical School.
About BryoLogyxBryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies.. The is capitalizing on two recent scientific advances: the discovery that a complex natural product, bryostatin, stimulates tumor antigen production to amplify the immune response unleashed by cancer immunotherapy; and the invention of the first practical synthetic production method for bryostatin and analogs, enabling their availability for commercial development. BryoLogyx has exclusive rights from Stanford University to the method’s use in cancer and a wide range of other therapeutic areas. Bryostatin-1 is expected to enter Phase 1b clinical trials in 2020 to study its potential role in enhancing immuno-oncology drugs in the treatment of hematologic (blood) cancers. Learn more at www.bryologyx.com.
